Yasuhiro Nakagiri

Yasuhiro Nakagiri

Active Director Additional Director DIN 07796678
DIN 07796678 First appointment Apr 2017 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 2 historical roles
Total affiliations 5 Since Apr 2017
Shareholding value •••• Premium profile

About Yasuhiro Nakagiri

Data last updated:

Yasuhiro Nakagiri is an Additional Director at Medreich Limited (since 2024), Director at Adcock Ingram Limited (since 2024) and Director at Adcock Ingram Pharma Private Limited (since 2024). The companies operate in Pharma and Business Services. The 3 current companies with reported revenue have a combined latest revenue of ₹2,248 Cr; the largest is Medreich Limited at ₹1,737 Cr (FY 2024). Earlier, Yasuhiro Nakagiri was a Managing Director at Astellas Pharma India Private Limited (2017–2020) and Director at Organisation Of Pharmaceutical Producers Of India (2017–2020).

DIN 07796678
Primary Designation Additional Director
Industry Pharma
First Appointment 01 Apr 2017
Oldest Company Age 53 yrs
Largest company Medreich Limited · ₹1,737 Cr (FY 2024)
Combined revenue ₹2,248 Cr across 3 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Medreich Limited U24232KA1973PLC002383
Additional Director09 May 20241973₹1,737 Cr (FY 2024)Active
Adcock Ingram Limited U24232KA2007PLC042361
Director08 May 20242007₹464 Cr (FY 2025)Active
Adcock Ingram Pharma Private Limited U24299KA2021PTC148184
Director08 May 20242021₹47.27 Cr (FY 2025)Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Managing Director29 Sep 20172008₹68.97 Cr (FY 2025)Active
Director01 Apr 20171965₹15.58 Cr (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Medreich Limited
Adcock Ingram Limited
Adcock Ingram Pharma Private Limited
Astellas Pharma India Private Limited
Premium access

Shareholding and investment profile for Yasuhiro Nakagiri

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Yasuhiro Nakagiri

Yasuhiro Nakagiri currently holds 3 directorships: Medreich Limited (Additional Director, since 09 May 2024, revenue ₹1,737 Cr (FY 2024)); Adcock Ingram Limited (Director, since 08 May 2024, revenue ₹464 Cr (FY 2025)); Adcock Ingram Pharma Private Limited (Director, since 08 May 2024, revenue ₹47.27 Cr (FY 2025)).

Yasuhiro Nakagiri was first appointed on 01 Apr 2017 as Director at Organisation Of Pharmaceutical Producers Of India. The most recent appointment on record is 09 May 2024 at Medreich Limited.

The 3 current companies of Yasuhiro Nakagiri that report revenue have a combined latest revenue of ₹2,248 Cr: Medreich Limited ₹1,737 Cr (FY 2024); Adcock Ingram Limited ₹464 Cr (FY 2025); Adcock Ingram Pharma Private Limited ₹47.27 Cr (FY 2025).

Yasuhiro Nakagiri held 2 earlier board appointments: Astellas Pharma India Private Limited (Managing Director, 29 Sep 2017 to 19 Jun 2020); Organisation Of Pharmaceutical Producers Of India (Director, 01 Apr 2017 to 31 Mar 2020).

The current boards of Yasuhiro Nakagiri's companies include Kenshi Murase (Medreich Limited), Misa Hirose (Medreich Limited), Pankaj Garg (Medreich Limited), Ramapuram Sreenivasulu Reddy (Medreich Limited), Ryoji Kikuchi (Medreich Limited), Tsutomu Yamada (Medreich Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available